[vc_row][vc_column width=”1/2″][vc_column_text]
OMRF researchers have identified a compound that has been successfully shown to decrease both tumor size and tumor vasculature in animal models of Glioblastoma Multiforme (GBM), an aggressive type of malignant brain tumor.[/vc_column_text][/vc_column][vc_column width=”1/4″][rd_vline color=”#1e73be”][/vc_column][vc_column width=”1/4″][vc_column_text]Year Founded: 2012
Year Partnered: 2012
Category: Biotech/Pharma
Fund: Oklahoma Seed Capital Fund
Acquired in 2016 by Oblato, Inc.[/vc_column_text][/vc_column][/vc_row]